Meeting
2017 ASCO Annual Meeting
A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
Authors
Dwight Hall Owen
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Dwight Hall Owen , Paul A. Bunn Jr., Bruce E. Johnson , David J. Kwiatkowski , Mark G. Kris , Ignacio Ivan Wistuba , Mayank Gandhi , See Phan , David S. Shames , Katja Schulze , Wei Yu , Dara Aisner , Jamie E. Chaft , Edward B. Garon , Jay M Lee , John D. Minna , Valerie W. Rusch , Karen L. Reckamp , Antoinette J. Wozniak , David P. Carbone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02927301
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS8580)
DOI
10.1200/JCO.2017.35.15_suppl.TPS8580
Abstract #
TPS8580
Poster Bd #
313b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2023 ASCO Annual Meeting
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
First Author: Antoine Italiano
Poster
2022 ASCO Annual Meeting
PD-L1 score as a prognostic biomarker in Asian patients with early-stage, EGFR-mutated lung cancer.
First Author: Stephanie Saw
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.
First Author: Greg Andrew Durm